Core Viewpoint - Chongqing Zhifei Biological Products Co., Ltd.'s subsidiary, Chongqing Chanan Biopharmaceutical Co., Ltd., has successfully completed the phase III clinical trial for CA508 injection, a dual insulin product for treating type 2 diabetes, demonstrating efficacy and safety comparable to the original drug [1][2]. Product Development Progress and Market Path - Following the completion of the phase III clinical trial, Chongqing Chanan Biopharmaceutical Co., Ltd. will submit a drug production registration application to the National Medical Products Administration, which must pass technical review and clinical site inspection before market approval [2]. - The successful development of CA508 injection signifies a significant breakthrough for Chongqing Chanan Biopharmaceutical Co., Ltd. in the diabetes treatment sector, with broad clinical application prospects [2]. Impact on Company Business Layout - Chongqing Zhifei Biological Products Co., Ltd. indicated that CA508 injection will not have a major short-term impact on overall company performance, but successful market approval could strengthen the company's treatment segment within its integrated "prevention & treatment" business layout [3]. - The strategic extension into therapeutic drugs, particularly in diabetes treatment, reflects the company's commitment to diversifying beyond its traditional vaccine business, laying a solid product foundation for long-term development [3].

Core Viewpoint - The announcement indicates that Zhifei Biological's subsidiary, Chongqing Chen'an Biological Pharmaceutical Co., Ltd., has completed the Phase III clinical trial summary report for the insulin injection CA508, demonstrating comparable efficacy and safety to the original drug, NovoRapid® [1] Group 1: Clinical Trial Results - The CA508 insulin injection has shown effectiveness and safety comparable to the original NovoRapid® insulin injection [1] - The clinical trial design meets the requirements outlined in the "Guidelines for Clinical Trials of Diabetes Drugs and Biological Products" regarding efficacy and safety evaluation [1] Group 2: Market Context - As of the announcement date, there is only one other domestic company that has received approval for a similar insulin injection product [1]

Core Viewpoint - Chongqing Zhifei Biological Products Co., Ltd. has achieved a significant breakthrough in the treatment of metabolic diseases with the successful completion of Phase III clinical trials for its CA508 injection, paving the way for future product registration [1][2]. Group 1: Product Development - The CA508 injection is a new generation of dual insulin formulation, combining long-acting insulin (degludec) and rapid-acting insulin (aspart), which allows for precise control of both baseline and postprandial blood sugar levels while significantly reducing the risk of hypoglycemia [2]. - The formulation is designed for ease of use, requiring only 1-2 injections per day without the need for mixing prior to use, thereby improving patient compliance [2]. Group 2: Clinical Trial Details - The Phase III clinical trial was led by Peking University People's Hospital and involved 40 research centers across China, employing a multi-center, randomized, open-label, parallel-controlled design [2]. - The trial focused on type 2 diabetes patients who had poor blood sugar control after previous treatment with basal or premixed insulin, addressing an unmet clinical need [2]. - The clinical trial summary report indicates that CA508 injection's efficacy and safety are comparable to the original drug, providing a solid basis for subsequent registration applications [2]. Group 3: Market Landscape - As of the announcement date, only one other company has a similar product approved in the domestic market, positioning CA508 injection as a promising local innovative treatment option for type 2 diabetes patients [3]. - Zhifei Biological aims to accelerate the transformation of research results into practical applications, guided by public health needs [3].